# US 2021/0198376 A1 · Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198376 A1
- Document ID: US20210198376A1
- Status: Published application
- Kind: A1
- Application number: 16/079,068
- Filed: 2018-06-01
- Published: 2021-07-01
- Earliest claimed: 2017-08-10
- Assignees: Grifols Diagnostic Solutions Inc.
- Applicants: Grifols Diagnostic Solutions Inc.
- Inventors: VINCENZO FAVALORO; MATTEO BINDA; JOHN A. HALL; ELIZABETH BOOTH; JODY BERRY; PETER A. SCHWIND
- Web page: https://patentgrep.com/patent/US20210198376A1

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- C07K 2319/21: containing a His-tag
- C07K 2319/24: containing a MBP (maltose binding protein)-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.

## Claims

### Claim 1

A composition for binding to an anti-CD38 antibody, the composition comprising a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with a binding activity of an anti-CD38 antibody, wherein a sequence of the recombinant soluble form of the extracellular domain of CD38 and/or the fragment thereof is selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the size of the recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof ranges from about 5 amino acids to about 300 amino acids.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the anti-CD38 antibody is against human CD38, non-human CD38, or a combination thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the anti-CD38 antibody is monoclonal, polyclonal, or a combination thereof.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the anti-CD38 antibody is selected from the group consisting of Darzalex, isatuximab, and MOR202.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof is expressed in a eukaryotic expression system or a prokaryotic expression system.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the concentration of the recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof ranges from about 1 mg/ml to about 400 mg/ml.

### Claim 8 (depends on 1)

A kit for bio-monitoring research and diagnostic assays, comprising the composition according to claim 1, a plate and reagents for identifying the presence of antibodies.

### Claim 9 (depends on 8)

The kit of claim 8, wherein the plate and reagents of the kit are configured for an ELISA assay.

### Claim 10 (depends on 9)

The kit according to claim 9, wherein the plate and reagents of the kit are those from an assay kit sold under the registered mark PROMONITOR®.

### Claim 11 (depends on 1)

A method of neutralizing or blocking binding of an anti-CD38 antibody in a sample, the method comprising:
providing a volume of the sample comprising the anti-CD38 antibody; and
incubating with a volume of the composition according to claim 1 sufficient to neutralize the anti-CD38 antibody in the sample.

### Claim 12 (depends on 11)

The method of claim 11, wherein the sample is selected from the group consisting of blood, plasma, and serum.

### Claim 13 (depends on 11)

The method of claim 11, wherein the anti-CD38 antibody is selected from the group consisting of Darzalex, isatuximab, and MOR202.

### Claim 14 (depends on 11)

The method of claim 11, wherein the volume of the sample ranges from about 25 μl to about 250 μl.

### Claim 15 (depends on 11)

The method of claim 11, wherein the volume of the composition ranges from about 0.5 μl to about 50 μl.

### Claim 16 (depends on 11)

The method of claim 11, wherein the concentration of the anti-CD38 antibody in the sample ranges from about 0.005 μg/ml to about 2000 μg/ml.

### Claim 17 (depends on 11)

The method of claim 11, wherein the concentration of the recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof in the composition ranges from about 1 mg/ml to about 400 mg/ml.

### Claim 18 (depends on 11)

The method of claim 11, wherein the neutralizing effect of the recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof ranges from about 70% to about 100%.

### Claim 19 (depends on 11)

The method of claim 11, wherein the binding activity of anti-CD38 antibody is selected from the group consisting of interference with blood pre-transfusion testing, interference with blood compatibility testing, and interference with antibody therapy.

### Claim 20 (depends on 11)

A method for delivering a unit of blood to a patient treated with anti-CD38 antibodies, the method comprising:
obtaining a sample from the patient, said sample being blood or a sample derived from blood of the patient;
neutralizing the anti-CD38 antibodies in the sample according to the method of claim 11;
testing the sample for compatibility with the unit of blood;
selecting the unit of blood that is compatible with the sample based on the testing; and
delivering the selected unit of blood to the patient.

### Claim 21 (depends on 1)

A method for removing anti-CD38 in human plasma, serum and/or blood during treatment of the plasma, serum, and/or blood, comprising exposing the plasma, serum, and/or blood to the composition of claim 1, wherein the recombinant soluble form of the extracellular domain of CD38 and/or the fragment thereof is tagged with an affinity tag.

### Claim 22 (depends on 21)

The method of claim 21, wherein the treatment comprises a treatment selected from the group consisting of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, plasma exchange therapy, and plasmapheresis.

### Claim 23 (depends on 21)

The method of claim 21, wherein the affinity tag is selected from the group consisting of Glutathione S-Transferase (GST), small ubiquitin-like modifiers (SUMO), AviTag, Calmodulin-tag, polyglutamate tag, E-tag, FLAG-tag, HA-tag, His-tag, Myc-tag, NE-tag, S-tag, SBP-tag, Softag 1, Softag 3, Strep-tag, TC tag, V5 tag, VSV-tag, Xpress tag, Isopeptag, SpyTag, SnoopTag, Biotin Carboxyl Carrier Protein (BCCP), Glutathione-S-transferase-tag, Green fluorescent protein-tag, other fluorescent protein tags, HaloTag, Maltose binding protein-tag, Nus-tag, Thioredoxin-tag, Fc-tag, Designed Intrinsically Disordered tags containing disorder promoting amino acids, and Ty tag.

### Claim 24

A fusion protein comprising a recombinant polypeptide fused to an oligomerization tag, wherein the oligomerization tag comprises an immunoglobulin Fc region or a fragment thereof and a polyHis domain.

### Claim 25 (depends on 24)

The fusion protein of claim 24 wherein the oligomerization tag is configured to form higher order of dimers up to 12mer or a hexamer of 2mer.

### Claim 26 (depends on 24)

The fusion protein of claim 24, wherein the polyHis domain has between 4 to 24 histidine residues.

### Claim 27 (depends on 24)

The fusion protein of claim 24, wherein the polyHis domain has between 6 to 10 histidine residues.

### Claim 28 (depends on 24)

The fusion protein of claim 24, wherein the polyHis domain has 6, 8 or 10 histidine residues.

### Claim 29 (depends on 24)

The fusion protein of claim 24, wherein the sequence of the immunoglobulin Fc region is SEQ ID NO: 15.

### Claim 30 (depends on 24)

The fusion protein of claim 24, wherein the sequence of the immunoglobulin Fc region has at least 90% identity to SEQ ID NO 15.

### Claim 31 (depends on 24)

The fusion protein of claim 24, wherein the sequence of the recombinant polypeptide and/or the fragment thereof is selected from the group consisting of SEQ ID NO; 1, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO 27.

### Claim 32 (depends on 24)

The fusion protein of claim 24, wherein the sequence of the fusion protein and/or the fragment thereof is selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 12, SEQ ID NO: 20, and SEQ ID NO: 21.

### Claim 33

An oligomerization tag for a recombinant fusion protein, the oligomerization tag comprising an immunoglobulin Fc region or a fragment thereof and a polyHis domain.

### Claim 34 (depends on 33)

The oligomerization tag of claim 33, wherein the polyHis domain has between 4 to 24 histidine residues.

### Claim 35 (depends on 33)

The oligomerization tag of claim 33, wherein the polyHis domain has between 6 to 10 histidine residues.

### Claim 36 (depends on 33)

The oligomerization tag of claim 33, wherein the polyHis domain has 6, 8 or 10 histidine residues.

### Claim 37 (depends on 33)

The oligomerization tag of claim 33, wherein the sequence of the immunoglobulin Fc region is SEQ ID NO: 15.

### Claim 38 (depends on 33)

The oligomerization tag claim 33, wherein the sequence of the immunoglobulin Fc region has at least 90% identity to SEQ ID NO 15.

### Claim 39 (depends on 33)

The oligomerization tag of claim 33, wherein the sequence of the oligomerization tag is selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18.

### Claim 40 (depends on 33)

A method for oligomerization of a recombinant fusion protein, the method comprising the steps of:
a) obtaining a genetically fused nucleotide sequence by genetically fusing a nucleotide sequence coding for an oligomerization tag according to claim 33 to a nucleotide sequence coding for a polypeptide;
b) obtaining a recombinant fusion protein by expressing the genetically fused nucleotide sequence of step a) in a host cell;
c) purifying the recombinant fusion protein obtained in step b);
d) oligomerizing the recombinant fusion protein.
